Recommendations regarding indications for treatment in CLL
| . | General practice . | Clinical trial . |
|---|---|---|
| Treat with Rai stage 0 | NGI* | RQ |
| Treat with Binet stage A | NGI* | RQ |
| Treat with Binet stage B or Rai stage I or II | Possible* | Possible* |
| Treat with Binet stage C or Rai stage III or IV† | Yes | Yes |
| Treatment of active/progressive disease | Yes | Yes |
| Treat without active/progressive disease | No | RQ |
| . | General practice . | Clinical trial . |
|---|---|---|
| Treat with Rai stage 0 | NGI* | RQ |
| Treat with Binet stage A | NGI* | RQ |
| Treat with Binet stage B or Rai stage I or II | Possible* | Possible* |
| Treat with Binet stage C or Rai stage III or IV† | Yes | Yes |
| Treatment of active/progressive disease | Yes | Yes |
| Treat without active/progressive disease | No | RQ |
General practice is defined as the use of accepted treatment options for a CLL patient not enrolled on a clinical trial. Early therapy of CLL is generally not recommended outside of clinical trials; however, we recognize the need to conduct clinical trials testing the early use of novel agents.
RQ, research question.
Treatment is indicated, if the disease is active as defined in section 4.
Anemia and/or thrombocytopenia from CLL-unrelated causes should be excluded.